253 related articles for article (PubMed ID: 22143118)
1. Human papillomavirus vaccine and men: what are the obstacles and challenges?
Stupiansky NW; Alexander AB; Zimet GD
Curr Opin Infect Dis; 2012 Feb; 25(1):86-91. PubMed ID: 22143118
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccine: a paradigm shift for pediatricians.
Jenson HB
Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
5. HPV vaccine and males: issues and challenges.
Zimet GD; Rosenthal SL
Gynecol Oncol; 2010 May; 117(2 Suppl):S26-31. PubMed ID: 20129653
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine acceptability among young adult men.
Gerend MA; Barley J
Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
[TBL] [Abstract][Full Text] [Related]
7. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
8. Acceptability of human papillomavirus vaccine for males: a review of the literature.
Liddon N; Hood J; Wynn BA; Markowitz LE
J Adolesc Health; 2010 Feb; 46(2):113-23. PubMed ID: 20113917
[TBL] [Abstract][Full Text] [Related]
9. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccine: recommendations, issues and controversies.
Fisher R; Darrow DH; Tranter M; Williams JV
Curr Opin Pediatr; 2008 Aug; 20(4):441-5. PubMed ID: 18622201
[TBL] [Abstract][Full Text] [Related]
11. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
Dasbach EJ; Elbasha EH; Insinga RP
Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
[TBL] [Abstract][Full Text] [Related]
12. Prevention strategies against human papillomavirus in males.
Garland SM
Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of human papillomavirus vaccination in developed countries.
Brisson M; Van de Velde N; Boily MC
Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
[TBL] [Abstract][Full Text] [Related]
14. Getting to know human papillomavirus (HPV) and the HPV vaccines.
Smith GD; Travis L
J Am Osteopath Assoc; 2011 Mar; 111(3 Suppl 2):S29-34. PubMed ID: 21415377
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
17. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
19. Improving adolescent health: focus on HPV vaccine acceptance.
Zimet GD
J Adolesc Health; 2005 Dec; 37(6 Suppl):S17-23. PubMed ID: 16310137
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV) vaccines: a Canadian update.
Foerster V; Murtagh J
Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
